Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Lung Neoplasms

Urinary Bladder Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Urologic Diseases

Male Urogenital Diseases

Antineoplastic Agents

All Drugs and Chemicals

Anti-Arrhythmia Agents

Vasodilator Agents

Analgesics

Trastuzumab

Ado-Trastuzumab Emtansine

Adenosine

Maytansine

Antineoplastic Agents, Immunological

Tubulin Modulators

Antimitotic Agents

Immunotoxins

Immunoconjugates

Immunologic Factors

Ado-trastuzumab emtansine is administered intravenously at 3.6 mg/kg every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.

ado-trastuzumab emtansine

Bob Li, MD

Gopakumar Iyer, MD

The purpose of this study is to find out what effects, a drug called ado-trastuzumab emtansine has on the patient and their cancer which is thought to be controlled by the abnormal HER2 gene.

Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

A Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

As soon as evaluations for each tumor assessment are completed, the Investigator should assess the patient's overall response (target plus non- target lesions) based on criteria and overall response algorithms as defined in RECIST version 1.1. Scans must be assessable for all evaluations.

Genentech, Inc.

Memorial Sloan Kettering Cancer Center

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers	NCT02675829	Solid Tumor Can... Lung Cancer Bladder Cancer Urinary Tract C...	ado-trastuzumab...	18 Years -	Memorial Sloan Kettering Cancer Center
Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers	NCT02675829	Solid Tumor Can... Lung Cancer Bladder Cancer Urinary Tract C...	ado-trastuzumab...	18 Years -	Memorial Sloan Kettering Cancer Center

Spots Global Cancer Trial Database for urinary tract cancers